Prospective Clinical Trial Evaluating Metronomic Chemotherapy in Patients With High-grade, Operable, Non-metastatic Osteosarcoma of the Extremity
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02273583|
Recruitment Status : Unknown
Verified February 2016 by Antônio Sérgio Petrilli, Grupo de Apoio ao Adolescente e a Crianca com Cancer.
Recruitment status was: Recruiting
First Posted : October 24, 2014
Last Update Posted : February 11, 2016
|Condition or disease||Intervention/treatment||Phase|
|High Grade Osteosarcoma||Drug: continuous oral cyclophosphamide and methotrexate||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||738 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||May 2006|
|Actual Primary Completion Date :||June 2013|
Experimental: Maintenance therapy
73 weeks of continuous oral low dose chemotherapy with cyclophosphamide (CPM) and methotrexate (MTX) following 31 weeks of MAP.
Drug: continuous oral cyclophosphamide and methotrexate
No Intervention: Control
31 weeks of MAP.
- Event-Free Survival [ Time Frame: EFS AT 5 YEARS ]AT 5 YEARS
- Overall survival [ Time Frame: OS AT 5 YEARS ]AT 5 YEARS
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02273583
|Contact: Sérgio Antônio Petrilli, MDemail@example.com|
|GRAACC- Institute of Pediatric Oncology||Recruiting|
|São Paulo, SP, Brazil, 04023-062|
|Contact: Antônio Sérgio Petrilli, MD 55-11-5080-8494 firstname.lastname@example.org|
|Principal Investigator: Antônio Sérgio Petrilli, MD|